Genomic Profiling of Small-Bowel Adenocarcinoma
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Small-bowel adenocarcinomas (SBAs) are rare cancers with a significantly lower incidence, later stage at diagnosis, and worse overall survival than other intestinal-derived cancers. To date, comprehensive genomic analysis of SBA is lacking. OBJECTIVE: To perform in-depth genomic characterization of a large series of SBAs and other gastrointestinal tumors to draw comparisons and identify potentially clinically actionable alterations. DESIGN, SETTING, AND PARTICIPANTS: Prospective analysis was performed of clinical samples from patients with SBA (n = 317), colorectal cancer (n = 6353), and gastric carcinoma (n = 889) collected between August 24, 2012, and February 3, 2016, using hybrid-capture-based genomic profiling, at the request of the individual treating physicians in the course of clinical care for the purpose of making therapy decisions. RESULTS: Of the 7559 patients included in analysis, 4138 (54.7%) were male; the median age was 56 (range, 12-101) years. The frequency of genomic alterations seen in SBA demonstrated distinct differences in comparison with either colorectal cancer (APC: 26.8% [85 of 317] vs 75.9% [4823 of 6353], P < .001; and CDKN2A: 14.5% [46 of 317] vs 2.6% [165 of 6353], P < .001) or gastric carcinoma (KRAS: 53.6% [170 of 317] vs 14.2% [126 of 889], P < .001; APC: 26.8% [85 of 317] vs 7.8% [69 of 889], P < .001; and SMAD4: 17.4% [55 of 317] vs 5.2% [46 of 889], P < .001). BRAF was mutated in 7.6% (484 of 6353) of colorectal cancer and 9.1% (29 of 317) of SBA samples, but V600E mutations were much less common in SBA, representing only 10.3% (3 of 29) of BRAF-mutated cases. The ERBB2/HER2 point mutations (8.2% [26 of 317]), microsatellite instability (7.6% [13 of 170]), and high tumor mutational burden (9.5% [30 of 317]) were all enriched in SBA. Significant differences were noted in the molecular profile of unspecified SBA compared with duodenal adenocarcinoma, as well as in inflammatory bowel disease-associated SBAs. Targetable alterations in several additional genes, including PIK3CA and MEK1, and receptor tyrosine kinase fusions, were also identified in all 3 series. CONCLUSIONS AND RELEVANCE: This study presents to our knowledge the first large-scale genomic comparison of SBA with colorectal cancer and gastric carcinoma. The distinct genomic differences establish SBA as a molecularly unique intestinal cancer. In addition, genomic profiling can identify potentially targetable genomic alterations in the majority of SBA cases (91%), and the higher incidence of microsatellite instability and tumor mutational burden in SBA suggests a potential role for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 1×
“Age, median (range), y 60 (18-86) 56 (13-101) 58 (12-88)”
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Self-citationMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“Age, median (range), y 60 (18-86) 56 (13-101) 58 (12-88)”
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
Pochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,424
PD-1 blockade in tumors with mismatch repair deficiency.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B., Kemberling, H., Eyring, A., Skora, A., Azad, N. S., Laheru, D. A., Donehower, R. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.lba100 · Cited by 565
Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats
DeSesso, J. M., & Jacobson, C. F. (2001) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(00)00136-8 · Cited by 528
Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors.
Miyaki, M., Konishi, M., Kikuchi‐Yanoshita, R., Enomoto, M., Igari, T., Tanaka, K., Muraoka, M., Takahashi, H., amada, Y. Y., & Fukayama, M. (1994) · PubMed · Cited by 412
A single-institution experience with 491 cases of small bowel adenocarcinoma
Halfdanarson, T. R., McWilliams, R. R., Donohue, J. H., & Quevedo, J. F. (2010) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2009.05.037 · Cited by 240
Self-citationYaeger, R., Shah, M. A., Miller, V. A., Kelsen, J. R., Wang, K., Heins, Z. J., Ross, J. S., He, Y., Sanford, E., Yantiss, R. K., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.001 · Cited by 200 · cited 1×
“Age, median (range), y 60 (18-86) 56 (13-101) 58 (12-88)”
Self-citationHaselkorn, T., Whittemore, A. S., & Lilienfeld, D. E. (2005) · Cancer Causes & Control · doi:10.1007/s10552-005-3635-6 · Cited by 182
Cremolini, C., Bartolomeo, M. D., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., Perrone, F., Tamborini, E., Aprile, G., Lonardi, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv290 · Cited by 173 · cited 1×
“Age, median (range), y 60 (18-86) 56 (13-101) 58 (12-88)”
Overman, M. J., Hu, C.-Y., Kopetz, S., Abbruzzese, J. L., Wolff, R. A., & Chang, G. J. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2173-6 · Cited by 172
Self-citationSmall bowel adenocarcinomas—existing evidence and evolving paradigms
Raghav, K., & Overman, M. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.132 · Cited by 172
Self-citationAmpullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation
Gingras, M., Covington, K. R., Chang, D. K.-F., Donehower, L. A., Gill, A. J., Ittmann, M., Creighton, C. J., Johns, A. L., Shinbrot, E., Dewal, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.005 · Cited by 156
Self-citationOverman, M. J., Hu, C., Wolff, R. A., & Chang, G. J. (2010) · Cancer · doi:10.1002/cncr.25324 · Cited by 131
Self-citationSmall bowel adenocarcinoma phenotyping, a clinicobiological prognostic study
Aparicio, T., Svrcek, M., Zaanan, A., Beohou, E., Laforest, A., Afchain, P., Mitry, E., Taïeb, J., Fiore, F. D., Gornet, J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.677 · Cited by 129 · cited 1×
“Age, median (range), y 60 (18-86) 56 (13-101) 58 (12-88)”
Self-citationERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma
Laforest, A., Aparicio, T., Zaanan, A., Pittella-Silva, F., Didelot, A., Desbeaux, A., Corre, D. L., Benhaïm, L., Pallier, K., Aust, D. E., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.007 · Cited by 106 · cited 1×
“Age, median (range), y 60 (18-86) 56 (13-101) 58 (12-88)”
Self-citationClinical detection and categorization of uncommon and concomitant mutations involving BRAF
Zheng, G., Tseng, L.-H., Chen, G., Haley, L., Illei, P., Gocke, C. D., Eshleman, J. R., & Lin, M.-T. (2015) · BMC Cancer · doi:10.1186/s12885-015-1811-y · Cited by 103 · cited 1×
“Age, median (range), y 60 (18-86) 56 (13-101) 58 (12-88)”
Ali, S. M., Sanford, E. M., Klempner, S. J., Rubinson, D. A., Wang, K., Palma, N. A., Chmielecki, J., Yelensky, R., Palmer, G. A., Morosini, D., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0378 · Cited by 83
Self-citationMutational activation of the RAS‐RAF‐MAPK and the wnt pathway in small intestinal adenocarcinomas
Bläker, H., Helmchen, B., Bönisch, A., Aulmann, S., Penzel, R., Otto, H. F., & Rieker, R. J. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410005847 · Cited by 67
Haan, J. C., Buffart, T. E., Eijk, P. P., van de Wiel, M. A., van Wieringen, W. N., Howdle, P. D., Mulder, C. J. J., van de Velde, C. J., Quirke, P., Nagtegaal, I. D., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr122 · Cited by 50 · cited 1×
“Age, median (range), y 60 (18-86) 56 (13-101) 58 (12-88)”
Rankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0148 · Cited by 40
Self-citationCetuximab in small bowel adenocarcinoma: a new friend?
Santini, D., Fratto, M. E., Spoto, C., Russo, A., Galluzzo, S., Zoccoli, A., Vincenzi, B., & Tonini, G. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605898 · Cited by 38
Yuan, W., Zhang, Z., Dai, B., Wei, Q., Liu, J., Liu, Y., Liu, Y., He, L., & Zhou, D. (2016) · Cancer · doi:10.1002/cncr.29974 · Cited by 37
Hall, M. J., Gowen, K. A., Sanford, E. M., Ali, S. M., Kaczmar, J. M., Miller, V. A., Stephens, P. J., Yelensky, R., Daly, M. B., & Sun, J. X. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.528 · Cited by 12
Self-citation
Cited by
Testa, U., Pelosi, E., & Castelli, G. (2018) · Medical Sciences · doi:10.3390/medsci6020031 · Cited by 374
Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Garrido-Laguna, I., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0043 · Cited by 269
Self-citationJiang, H., Yu, D., Yang, P., Guo, R., Kong, M., Gao, Y., Yu, X., Lu, X., & Fan, X. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.730 · Cited by 255
Integrative proteomic characterization of trace FFPE samples in early-stage gastrointestinal cancer
(2022) · doi:10.1186/s12953-022-00188-0 · Cited by 4
Metadata
- Authors
- Schrock, A. B., Devoe, C. E., McWilliams, R., Sun, J., Aparicio, T., Stephens, P. J., Ross, J. S., Wilson, R., Miller, V. A., Ali, S. M., & Overman, M. J.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-11-01
- Volume
- 3
- Issue
- 11
- Pages
- 1546
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2625048728
- Cited by
- 227
- References
- 28
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.